Biomarker systems (Biomasys) is a biotechnology start-up with a mission to bring rapid, affordable and easy-to-use diagnostics to a mass market. We are developing technology that applies Artificial Intelligence and novel protocols in Biomarker detection for this purpose. We have a founding team of well-credentialed and highly motivated biomedical science researchers who hail from Nigeria and Bangladesh and have received postgraduate degrees from the Universities of Cambridge, Manchester and Ilorin. Our research experience includes rapid diagnostic device development for tuberculosis, cost-effective methods of sex chromosome anomaly detection (for Swyer syndrome) and the use of AI in improving detection of early-onset triple-negative breast cancer (TNBC).